These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
462 related articles for article (PubMed ID: 3877518)
1. Differences in red cell behaviour between patients with Raynaud's phenomenon and systemic sclerosis and patients with Raynaud's disease. Rustin MH; Kovacs IB; Sowemimo-Coker SO; Maddison PJ; Kirby JD Br J Dermatol; 1985 Sep; 113(3):265-72. PubMed ID: 3877518 [TBL] [Abstract][Full Text] [Related]
2. Altered behaviour of erythrocytes in scleroderma. Kovacs IB; Sowemimo-Coker SO; Kirby JD; Turner P Clin Sci (Lond); 1983 Nov; 65(5):515-9. PubMed ID: 6617097 [TBL] [Abstract][Full Text] [Related]
3. [Erythrocyte filterability in Raynaud's disease]. Sciannameo F; Francucci M; Cao PG; Marianeschi P; Valentini M; Tockner M; Sassano L; Grasselli A Ric Clin Lab; 1983; 13 Suppl 3():475-80. PubMed ID: 6673030 [TBL] [Abstract][Full Text] [Related]
4. Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis. O'Reilly D; Taylor L; el-Hadidy K; Jayson MI Ann Rheum Dis; 1992 Nov; 51(11):1193-6. PubMed ID: 1466594 [TBL] [Abstract][Full Text] [Related]
5. Effect of prostaglandins I2 and E1 on red cell deformability in patients with Raynaud's phenomenon and systemic sclerosis. Dowd PM; Kovacs IB; Bland CJ; Kirby JD Br Med J (Clin Res Ed); 1981 Aug; 283(6287):350. PubMed ID: 6788326 [No Abstract] [Full Text] [Related]
6. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis. Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043 [TBL] [Abstract][Full Text] [Related]
7. Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynaud's syndrome. Belch JJ; McLaren M; Anderson J; Lowe GD; Sturrock RD; Capell HA; Forbes CD; Mikhailidis DP; Jeremy JY; Dandona P Prostaglandins Leukot Med; 1985 Jun; 18(3):401-2. PubMed ID: 3895252 [No Abstract] [Full Text] [Related]
8. Plasma beta-thromboglobulin in the differential diagnosis of Raynaud's phenomenon. Seibold JR; Harris JN J Rheumatol; 1985 Feb; 12(1):99-103. PubMed ID: 2580093 [TBL] [Abstract][Full Text] [Related]
9. Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon. Biondi ML; Marasini B; Bianchi E; Agostoni A Int J Cardiol; 1988 Jun; 19(3):335-9. PubMed ID: 3397197 [TBL] [Abstract][Full Text] [Related]
10. The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study. Virgili-Gervais G; Matthews B; Nassar EL; Carrier ME; Kwakkenbos L; Pauling JD; Bartlett SJ; Gietzen A; Gottesman K; Guillot G; Hudson M; Hummers LK; Lawrie-Jones A; Malcarne VL; Mayes MD; Richard M; Sauvé M; Wojeck RK; Mouthon L; Benedetti A; Thombs BD; Lancet Rheumatol; 2024 Oct; 6(10):e684-e692. PubMed ID: 39216493 [TBL] [Abstract][Full Text] [Related]
12. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies. Kallenberg CG; Pastoor GW; Wouda AA; The TH Ann Rheum Dis; 1982 Aug; 41(4):382-7. PubMed ID: 7051989 [TBL] [Abstract][Full Text] [Related]
13. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis]. Serri J; Legré R; Veit V; Guardia C; Gay AM Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894 [TBL] [Abstract][Full Text] [Related]
14. Altered microrheological parameters in Raynaud's phenomenon. Papp J; Sandor B; Toth A; Biro K; Rabai M; Botor D; Kovacs D; Csernus Z; Toth K; Kesmarky G Clin Hemorheol Microcirc; 2017; 65(1):23-29. PubMed ID: 27258205 [TBL] [Abstract][Full Text] [Related]
15. Increased urinary pyridinoline cross-link compounds of collagen in patients with systemic sclerosis and Raynaud's phenomenon. Istok R; Czirják L; Lukác J; Stancíková M; Rovenský J Rheumatology (Oxford); 2001 Feb; 40(2):140-6. PubMed ID: 11257149 [TBL] [Abstract][Full Text] [Related]
16. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon. Kahan A; Amor B; Menkes CJ Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061 [TBL] [Abstract][Full Text] [Related]
17. [Hemorrheology and neurovascular syndromes of the extremities]. Sergio G; Artale F; Francisci A; Giunti P; Perego MA Ric Clin Lab; 1983; 13 Suppl 3():481-5. PubMed ID: 6673031 [TBL] [Abstract][Full Text] [Related]
18. Increased nailfold capillary dimensions in primary Raynaud's phenomenon and systemic sclerosis. Bukhari M; Herrick AL; Moore T; Manning J; Jayson MI Br J Rheumatol; 1996 Nov; 35(11):1127-31. PubMed ID: 8948300 [TBL] [Abstract][Full Text] [Related]
19. Cutaneous microcirculation in systemic sclerosis and response to intra-arterial reserpine. Nilsen KH; Jayson MI Br Med J; 1980 Jun; 280(6229):1408-11. PubMed ID: 7427134 [TBL] [Abstract][Full Text] [Related]
20. Calcium influx into red blood cells: the effect of sera from patients with systemic sclerosis. Rademaker M; Thomas RH; Kirby JD; Kovacs IB Clin Exp Rheumatol; 1991; 9(3):247-51. PubMed ID: 1879084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]